Loading organizations...
Loading organizations...
Monogram Health delivers value-based, multispecialty, in-home care for individuals managing complex chronic conditions. The company employs an evidence-based approach for disease diagnosis, treatment, and medication management, alongside patient education. This model aims to improve health outcomes by providing specialized, integrated care directly to patients in their homes.
Michael Uchrin and former U.S. Senator Bill Frist founded Monogram Health in 2019, incubated by Frist Cressey Ventures. The company was born from the insight into fragmented care for complex chronic illnesses, notably kidney disease. The founders aimed to create a proactive, integrated, and personalized care model, shifting beyond traditional clinical settings.
Monogram Health serves patients with multiple chronic conditions, particularly kidney disease, partnering with payers to deliver its care model. Its vision is to transform chronic disease management by decentralizing care to the home, enhancing engagement and improving health outcomes. The company strives for more effective pathways for its patient population.
Monogram Health has raised $922.0M across 4 funding rounds.
Monogram Health has raised $922.0M in total across 4 funding rounds.
Monogram Health has raised $922.0M in total across 4 funding rounds.
Monogram Health's investors include Cigna Ventures, CVS Health Ventures, Bill Frist, Heritage Group, Humana, Memorial Hermann Health System, Norwest Venture Partners, Pura Vida Investments, SCAN Group, Kendall Garrison, Scale Venture Partners, Todd Sisitsky.
Monogram Health is a value-based multispecialty provider delivering in-home, evidence-based care and benefit management services primarily for patients with chronic kidney disease (CKD), end-stage kidney disease (ESKD), and related polychronic conditions like diabetes, hypertension, heart failure, COPD, and metabolic disorders.[1][2][3][4] It serves high-risk, medically complex patients across 33-36 states through partnerships with major health plans, integrated delivery systems, and risk-bearing primary care platforms, employing nephrologists, cardiologists, endocrinologists, pulmonologists, pharmacists, dietitians, social workers, and others for holistic treatment.[2][3][4][5] The company solves systemic gaps in fragmented healthcare—such as barriers to consistent care, poor outcomes, and high costs—via AI-driven predictions, proprietary EHR platforms, data analytics, and social supports, achieving 89% controlled blood pressure (39% above national average), 44% reduction in inpatient admissions, 52% drop in ER visits, and over 35% MLR savings on engaged members.[3][4] Founded in 2019 and backed by Frist Cressey Ventures, Norwest Venture Partners, and TPG Capital, it ranked as the third fastest-growing U.S. company in recent metrics, demonstrating strong growth momentum.[1][5]
Monogram Health was founded in 2019 in Brentwood (now Nashville), Tennessee, to address the fragmented U.S. healthcare system's failures for patients with CKD and compounding polychronic conditions, which lead to poor outcomes, care barriers, and reduced quality of life.[1][2][4] Co-founder and CEO Michael (Mike) Uchrin leads the effort, emphasizing clinical precision and human connection; alongside Chief Technology Officer Brian Loflin, the team built a model starting with a vision for personalized, in-home care symbolized by the "Monogram" name.[2][3][4] Early traction came from deploying AI algorithms for predictive care, proprietary tech platforms, and value-based partnerships, enabling rapid scaling to serve patients nationwide while earning accolades like HITRUST CSF Certification for data security and "Complex Chronic Disease Solutions Provider of the Year."[2][3]
Monogram Health rides the wave of value-based care and AI-driven chronic disease management, capitalizing on the U.S. chronic kidney disease epidemic affecting millions amid rising healthcare costs and polychronic comorbidities.[1][3][6] Its timing aligns with payer shifts toward risk-bearing models, post-COVID emphasis on home-based care, and AI adoption for predictive analytics, enabling interoperability with EHRs and real-time interventions that traditional clinic models can't match.[2][3] Market forces like Medicare Advantage growth and health equity mandates favor its holistic approach, which slows CKD progression, averts dialysis/transplants, and cuts utilization—positioning it against competitors like Strive Health or Carenostics while influencing ecosystem-wide adoption of tech-enabled, multispecialty in-home care for high-cost patients.[1][5]
Monogram Health's trajectory points to further national expansion, deeper AI enhancements for predictive precision, and more payer/health system integrations, potentially dominating polychronic care as value-based models mature.[3][5] Trends like AI interoperability, social determinants integration, and home health demand will propel it, evolving its influence from kidney-focused innovator to broader chronic care leader—redefining personalized medicine at scale, much like its founding vision to transform fragmented systems for healthier lives.[2][4][6]
Monogram Health has raised $922.0M across 4 funding rounds. Most recently, it raised $375.0M Other Equity in January 2023.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jan 10, 2023 | $375.0M Other Equity | Cigna Ventures, CVS Health Ventures, Bill Frist, Heritage Group, Humana, Memorial Hermann Health System, Norwest Venture Partners, Pura Vida Investments, SCAN Group, Kendall Garrison | |
| Jan 1, 2023 | $380.0M Series C | Norwest Venture Partners, Scale Venture Partners | |
| Jun 8, 2021 | $160.0M Series B | Todd Sisitsky | Frist Cressey Ventures, Humana, Norwest Venture Partners |
| May 1, 2020 | $7.0M Series A | Bill Frist, Casper de Clercq | Norwest Venture Partners, Scale Venture Partners |
